Skip to main content
. Author manuscript; available in PMC: 2009 May 4.
Published in final edited form as: Lab Invest. 2008 Jun 16;88(8):842–855. doi: 10.1038/labinvest.2008.55

Figure 1.

Figure 1

Expression of BMP7 correlates with melanoma progression in melanoma cell lines by qRT-PCR using normal melanocyte (FOM103) as control (A) and in situ by immunohistochemistry (B-F). Four isogenic cell pairs were analyzed by qRT-PCR, including: WM115 (primary melanoma, ■)/WM239A (metastatic melanoma, □); WM793 (primary melanoma, ■)/1205Lu (metastatic melanoma, □); WM983A (primary melanoma, ■)/WM983C (metastatic melanoma, □); and C81-61 (metastatic melanoma, ■)/C8161 (highly aggressive metastatic melanoma selected in experimental metastasis model in vivo, □). Paraffin sections of primary cutaneous melanoma (Magnification: 200X) and a panel of metastatic lesions in different organ sites (magnification: 400X), including skin (C), bone (D), brain (E), and lymph node (F), were subjected to immunohistochemistry as described in Materials and Methods. Comparing to the corresponding negative controls (inserts), BMP7 expression is evident in melanoma cells.